Figure 3B shows the highest plotted mean serum antibody concentrations for the 03-135 formulation at 24 and 48 hours. This is a qualitative comparison of the plotted means; the figure does not report a between-lipid statistical significance test.
| Chemical Name | Lipid 03-135 |
| Patent compound ID | 03-135; Compound 135 in WO2022152109A2 |
| Formula | C53H102N2O7 |
| M.Wt | 879.41 |
| SMILES | CCCCCCCCC(CCCCCC)COC(=O)CCCCCN(CCO)CCN(CCCCC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)C1CCC1 |
| Stereochemistry | Not specified in the patent structure |
| Salt / solvate | Neutral parent depicted; no counterion or solvate included |
| CAS No. | Not confirmed |
| Purity | >95% by ELSD-HPLC |
| Availability | Inquire for availability |
| Classification | Cationic/Ionizable Lipids |
SMILES, formula and average molecular weight are calculated from the redrawn neutral structure, not quoted as patent analytical measurements. The branch stereocenter is unassigned.
mRNA1 delivery · mouse expression study
| Cargo | mRNA1 encoding a CD19/CD3 bispecific antibody |
| Model | NOD/SCID mice |
| Administration | Intravenous (tail vein), single dose |
| Dose | 1 μg mRNA per mouse |
| Comparators | 01-1, 03-208, 02-1 and 02-3 |
| N/P ratio | Not reported for this experiment |
| Exact formulation | 03-135 with helper lipids described in Example 2. Component molar percentages and exact PEG-lipid identity are not resolved for Figure 3B. |
The result supports intravenous mRNA-encoded antibody delivery research. This patent does not disclose a 03-135-specific subcutaneous or monkey experiment. The antitumor experiment in Figure 4 uses lipid 01-1.
Source: WO2024131874A1, Figure 3B, PDF p. 137; Example 7, paragraph [0362].
Values shown are literature-reported results for the cited formulation and study conditions. They do not guarantee performance of the supplied product in other formulations or experiments.
Zhong X, Ying B, Du L, Yang Z, Qin Q, Yuan J. Polynucleotides encoding CD19/CD3 bispecific antibodies. Abogen Biosciences (Shanghai) Co., Ltd. WO2024131874A1. Published 27 June 2024. View patent ↗
Ying B, Wang X. Lipid compounds and lipid nanoparticle compositions. Suzhou Abogen Biosciences Co., Ltd. WO2022152109A2. Published 21 July 2022. Table 1, Compound 135, printed p. 60. View patent ↗
Structure identity
WO2024131874A1 Table 03-1, printed p. 53 (PDF p. 54); WO2022152109A2 Table 1, Compound 135, printed p. 60 (PDF p. 61).
Product documentation
Batch-specific COA and safety documentation: inquire for availability.